← 返回

用于 CAR-T 细胞癌症治疗的 ODE 系统参数估计的 MCMC 方法

英文原题:MCMC Methods for Parameter Estimation in ODE Systems for CAR-T Cell Cancer Therapy.

查看英文原题

MCMC Methods for Parameter Estimation in ODE Systems for CAR-T Cell Cancer Therapy.

PubMed 2024/09/11(内容时间) Cancers (Basel) Q2 · IF 4.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

嵌合抗原受体(CAR)-T细胞疗法是治疗耐药性血液系统恶性肿瘤的一项突破。它基于对来自患者或供者的T细胞进行基因修饰。尽管在过去几年中其应用有所增加,但CAR-T 仍有许多挑战需要解决,例如相关的严重毒性,如细胞因子释放综合征。为了模拟CAR-T 细胞动力学,重点关注其增殖和细胞毒性活性,我们开发了一个使用常微分方程(ODEs)并结合贝叶斯参数估计的数学框架。贝叶斯统计通过蒙特卡洛积分、贝叶斯推断和马尔可夫链蒙特卡洛(MCMC)方法用于估计模型参数。本文探讨了MCMC方法,包括Metropolis-Hastings算法以及DEMetropolis和DEMetropolisZ算法,这些算法整合了差分进化以提高收敛速度。理论发现和算法使用Python和Jupyter Notebooks进行了验证。分析了一个CAR-T 细胞疗法的真实医学数据集,采用优化算法使数学模型拟合数据,并借助PyMC库促进贝叶斯分析。

结果表明,我们的模型准确捕捉了CAR-T 细胞疗法的关键动力学。这一结论强调了参数估计在临床环境中提高对CAR-T 细胞疗法的理解和有效性的潜力。

展开英文摘要原文

Chimeric antigen receptor (CAR)-T cell therapy represents a breakthrough in treating resistant hematologic cancers. It is based on genetically modifying T cells transferred from the patient or a donor. Although its implementation has increased over the last few years, CAR-T has many challenges to be addressed, for instance, the associated severe toxicities, such as cytokine release syndrome. To model CAR-T cell dynamics, focusing on their proliferation and cytotoxic activity, we developed a mathematical framework using ordinary differential equations (ODEs) with Bayesian parameter estimation. Bayesian statistics were used to estimate model parameters through Monte Carlo integration, Bayesian inference, and Markov chain Monte Carlo (MCMC) methods.

This paper explores MCMC methods, including the Metropolis-Hastings algorithm and DEMetropolis and DEMetropolisZ algorithms, which integrate differential evolution to enhance convergence rates. The theoretical findings and algorithms were validated using Python and Jupyter Notebooks.

A real medical dataset of CAR-T cell therapy was analyzed, employing optimization algorithms to fit the mathematical model to the data, with the PyMC library facilitating Bayesian analysis. The results demonstrated that our model accurately captured the key dynamics of CAR-T cell therapy. This conclusion underscores the potential of parameter estimation to improve the understanding and effectiveness of CAR-T cell therapy in clinical settings.

论文信息

作者
Antonini E、Mu G、Sansaloni-Pastor S、Varma V、Kabak R
第一作者单位
Cilag GmbH International, 6300 Zug, Switzerland.Switzerland
通讯作者单位
Johnson & Johnson World Headqtrs US, Bridgewater, NJ 08807, USA.United States
期刊
Cancers2024 Sep 11
原文标识
PubMed 39335104 · DOI 10.3390/cancers16183132